What Happens to ADHD Telehealth in New Jersey After the DEA Deadline?

Numerous providers of controlled substances as medications, including some stimulants used to manage ADHD symptoms via telehealth, are beholden to Drug Enforcement Administration rules that run through December 31, 2026. The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 (or just the Ryan Haight Act) allows practitioners to prescribe controlled substances indefinitely via telehealth, after they’ve done at least one in-person medical evaluation.

Many schedule II stimulants affected by these laws are commonly prescribed to manage ADHD symptoms, which is why children and adults with ADHD should pay attention. These medications can’t be refilled, so they need a brand new prescription each time.

New Jersey, in particular, also changed its own stimulant-prescribing law on July 8. The state rules now work differently for adults and children, which is where much of the confusion starts.

Table of Contents

COVID’s Lingering Impacts on the Federal ADHD Telehealth Rule

COVID-era telemedicine flexibilities temporarily removed the prior in-person medical evaluation requirement for qualifying telemedicine prescribing. The DEA made temporary extensions, the latest of which runs through December 31, 2026.

Until then, DEA-registered practitioners may prescribe Schedule II through V controlled medications through audio-video telemedicine without first conducting that in-person medical evaluation, as long as the prescription complies with the rest of federal and state law.

New Jersey Changed the Adult Schedule on July 8

Governor Mikie Sherrill signed Assembly Bill 4852 on July 8, 2026, and the law took effect immediately.

For an adult starting a Schedule II stimulant through telehealth, New Jersey now allows the initial examination to happen by video. When care begins remotely, the patient must have an in-person visit within 30 days.

It’s easy to maintain the calendar from there. There needs to be an in-person visit at least every three months for Schedule II substances. The law requires at least one in-person visit each year rather than one every three months.

New Jersey also requires live, real-time audio and video when a Schedule II drug is prescribed through telemedicine. Regular phone calls won’t suffice.

Of course, practices themselves can set their own stricter policies. They have to abide by state law at minimum, but there’s nothing preventing them from going beyond.

The Children Exception

New Jersey makes an exception for patients under 18. A prescriber may prescribe a Schedule II stimulant through telemedicine without the state’s initial in-person examination requirement with a parent or guardian’s written consent.

The telemedicine appointment itself still has to use live two-way audio and video.

Parents using video visits for children and teens should ask whether the written consent is already in the child’s chart. That solves the New Jersey requirement, but whatever happens after December 31 is still up in the air.

The Federal Rule for January Is Still Being Finalized

Nobody knows what will happen with these rules come January 1st. As of the writing of this blog, the White House lists lists DEA’s final Special Registrations for Telemedicine rule, submitted on August 25, 2026, as under review.

We can reasonably speculate, however. There are three likely possibilities:

The DEA publishes the final rule, whatever it may be
The government extends the current rules again
The current rules expire without a replacement in place

That third outcome is the one families who have never met their prescriber in person should plan around. New Jersey’s written-consent exception for children only changes state law. It cannot waive a federal in-person medical evaluation requirement. But until the day comes, no practice can know exactly which parts of the current rules will survive.

Adults Should Check Who Conducted Their In-Person Visit

An adult who started stimulant treatment by video may already have completed New Jersey’s required in-person visit within the first 30 days.

But that doesn’t mean they can assume they’ve satisfied federal requirements. Under the standard Ryan Haight route, the prescribing practitioner is the one who conducts the qualifying in-person medical evaluation, subject to the law’s other exceptions.

Ask the prescriber’s office who conducted your in-person appointment and whether the practice considers it sufficient under the federal rules that would apply if the temporary flexibilities expire.

What to Ask Before December 31

The next telehealth appointment is a good time to get the dates and names straight. Ask:

Has the clinician who writes the stimulant prescription ever completed an in-person medical evaluation with my child or me? On what date?
What is the practice’s plan if the current DEA telemedicine flexibilities end on December 31?
For a patient who has only been seen by video, does the practice recommend scheduling an in-person appointment before the deadline?

Write the answers down with the date of any in-person visit. Adults also need to keep track of New Jersey’s 30-day requirement when stimulant treatment begins remotely. That deadline is easy to lose in an ordinary month, especially for someone already dealing with ADHD time blindness.

A prescription delay is also worth discussing before it happens. Ask which non-medication ADHD strategies can help support routines, schoolwork, sleep, or organization while a medication issue is being sorted out. They aren’t a replacement for a prescribed stimulant, but having a plan beforehand is better than inventing one after a problem starts.

Questions Parents and Adults Are Asking

Can an out-of-state telehealth company prescribe ADHD medication in New Jersey?

The clinician treating a patient located in New Jersey must hold the appropriate New Jersey license.

On August 31, 2026, the U.S. Court of Appeals for the Third Circuit upheld New Jersey’s physician-licensing requirement for telemedicine. The court found that physicians providing medical care virtually to patients in New Jersey can still be required to obtain a New Jersey medical license.

The Interstate Medical Licensure Compact may streamline the application process for eligible physicians, but it does not replace the New Jersey license. When comparing ADHD specialists online, verify the clinician’s New Jersey license rather than relying only on the telehealth company’s national coverage map.

Does the December 31 deadline affect video therapy or non-stimulant ADHD medication?

No. The federal deadline concerns the telemedicine prescribing of controlled medications.

Ordinary video therapy does not become prohibited because the temporary DEA prescribing flexibilities expire. Noncontrolled ADHD medications are also outside these specific Schedule II stimulant rules, although their ordinary prescribing and licensing requirements still apply.

When will families know what the final federal rule requires?

There is no published date.

DEA’s final special-registration rule remains under White House regulatory review as of October 6, 2026. The details will become public when the final rule is released, so families and practices should watch for the Federal Register publication rather than trying to infer the final requirements from the 2025 proposal.

What to Book Before the Deadline

Families using a psychiatrist by video who have never met the prescribing clinician in person should ask the practice now whether an in-person appointment before December 31 would reduce uncertainty for January.

An appointment is not a guarantee that every future federal requirement will be satisfied. The important question is whether the visit would qualify as the prescribing practitioner’s in-person medical evaluation under the federal rules that apply after the temporary flexibilities end.

Adults who begin stimulant treatment through video should handle New Jersey’s separate requirement at the same time by booking the required in-person visit within 30 days.

Federal telemedicine policy has changed repeatedly since 2020. Until the permanent system is settled, checking with the prescribing office before each new controlled-substance prescription is more reliable than assuming the rule from the last refill still applies.